Advertisement

Molecular Neurobiology

, Volume 51, Issue 3, pp 1452–1461 | Cite as

MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: a Meta-analysis

  • Dong Wei
  • Qun Wan
  • Li Li
  • Haifeng Jin
  • Yonghong Liu
  • Yangang Wang
  • Guangyun Zhang
Article

Abstract

Recent studies have shown abnormal microRNA (miRNA) expression levels in the central nervous system (CNS) of cancer patients, suggesting that miRNAs may serve as promising biomarkers for cancers of CNS. However, other studies have arrived at conflicting results. Therefore, this meta-analysis aims to systematically measure the potential diagnostic value of miRNAs for CNS cancers. Electronic databases as well as other sources were searched until to April 12, 2014 for relevant articles. Data from different studies were pooled using the random-effects model. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative LR (NLR), diagnostic odds ratio (DOR), together with the summary receiver operator characteristic (SROC) curve, and area under the SROC curve (AUC) value were used to estimate overall diagnostic performance. Twenty-three studies from 6 articles were included in the current meta-analysis with a total of 299 CNS cancer patients and 418 controls. The pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.85 (95 % CI, 0.80–0.89), 0.83 (95 % CI, 0.76–0.88), 5.1 (95 % CI, 3.4–7.5), 0.18 (95 % CI, 0.12–0.26), 28 (95 % CI, 14–58), and 0.91 (95 % CI, 0.88–0.93), respectively. Subgroup analyses showed that cerebrospinal fluid (CSF)-based miRNAs assays yielded more accurate results and seemed to be more sensitive in diagnosing of primary central nervous system lymphoma (PCNSL). In conclusion, miRNAs may be suitable for serving as noninvasive biomarkers for CNS cancers detection. However, further validation based on a larger sample of patients and controls is still required.

Keywords

MicroRNAs Central nervous system cancers Diagnosis Meta-analysis 

Notes

Sources of Funding

This work was funded by the National Nature Science Foundation of China (Numbers: 81372115, 81101504 and 31370834), a Foundation for the Author of National Excellent Doctoral Dissertation of PR China (Number: 201363).

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, Kalani MY (2010) The many roles of microRNAs in brain tumor biology. Neurosurg Focus. doi: 10.3171/2009.10.FOCUS09207 Google Scholar
  3. 3.
    Schafer N, Glas M, Herrlinger U (2012) Primary CNS lymphoma: a clinician’s guide. Expert Rev Neurother 12(10):1197–1206CrossRefPubMedGoogle Scholar
  4. 4.
    Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol 21(24):4489–4495CrossRefGoogle Scholar
  5. 5.
    Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci Off J Neurosurg Soc Australas 17(4):417–421Google Scholar
  6. 6.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMedGoogle Scholar
  7. 7.
    Ilhan-Mutlu A, Wagner L, Preusser M (2013) Circulating biomarkers of CNS tumors: an update. Biomark Med 7(2):267–285CrossRefPubMedGoogle Scholar
  8. 8.
    Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118(3):449–457CrossRefPubMedGoogle Scholar
  9. 9.
    Zheng PP, Hop WC, Sillevis Smitt PA, van den Bent MJ, Avezaat CJ, Luider TM, Kros JM (2005) Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res Off J Am Assoc Cancer Res 11(12):4388–4392CrossRefGoogle Scholar
  10. 10.
    Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65(12):5190–5194CrossRefPubMedGoogle Scholar
  11. 11.
    Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11):3140–3146CrossRefPubMedGoogle Scholar
  12. 12.
    Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H (2010) Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 85(6):520–528CrossRefPubMedGoogle Scholar
  13. 13.
    Kiewe P, Fischer L, Martus P, Thiel E, Korfel A (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro-Oncology 12(4):409–417CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Roth A, Storek B, Hummel M, Nagele T, Thiel E, Korfel A (2008) Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71(14):1102–1108. doi: 10.1212/01.wnl.0000326958.52546.f5 CrossRefPubMedGoogle Scholar
  15. 15.
    Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 26(1):96–105CrossRefGoogle Scholar
  16. 16.
    Kersten MJ, Evers LM, Dellemijn PL, van den Berg H, Portegies P, Hintzen RQ, van Lier RA, von dem Borne AE, van Oers RH (1996) Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood 87(5):1985–1989PubMedGoogle Scholar
  17. 17.
    Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels HJ (2010) Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 85(3):236–242CrossRefPubMedGoogle Scholar
  18. 18.
    Huang Y, Zou Q, Song H, Song F, Wang L, Zhang G, Shen X (2010) A study of miRNAs targets prediction and experimental validation. Protein Cell 1(11):979–986CrossRefPubMedGoogle Scholar
  19. 19.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRefPubMedGoogle Scholar
  20. 20.
    Li M, Li J, Ding X, He M, Cheng SY (2010) microRNA and cancer. AAPS J 12(3):309–317CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12CrossRefPubMedGoogle Scholar
  22. 22.
    Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866CrossRefPubMedGoogle Scholar
  23. 23.
    Thapa DR, Hussain SK, Tran WC, D’Souza G, Bream JH, Achenback CJ, Ayyavoo V, Detels R, Martinez-Maza O (2014) Serum micrornas in HIV-infected individuals as pre-diagnosis biomarkers for aids-related non-hodgkin lymphomas (aids-NHL). J Acquir Immune Defic Syndr 66(2):229–237PubMedGoogle Scholar
  24. 24.
    Mao X, Sun Y, Tang J (2014) Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35(2):233–238CrossRefPubMedGoogle Scholar
  25. 25.
    Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, Hahn S, Schroers R (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology 14(1):29–33CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY, Zhang C (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer J Int Cancer 132(1):116–127CrossRefGoogle Scholar
  27. 27.
    Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101(10):2087–2092CrossRefPubMedGoogle Scholar
  28. 28.
    Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(10):1721–1726CrossRefGoogle Scholar
  29. 29.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006CrossRefPubMedGoogle Scholar
  30. 30.
    Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMedGoogle Scholar
  31. 31.
    Mitchell AJ, Vaze A, Rao S (2009) Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374(9690):609–619CrossRefPubMedGoogle Scholar
  32. 32.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113, iiiCrossRefGoogle Scholar
  34. 34.
    Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. doi: 10.1186/1471-2288-6-31 PubMedCentralPubMedGoogle Scholar
  35. 35.
    Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119–1129CrossRefPubMedGoogle Scholar
  36. 36.
    Weller M, Martus P, Roth P, Thiel E, Korfel A (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology 14(12):1481–1484CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Nishikawa R (2012) Resection of PCNSL, if safely possible, seems to be better than biopsy: challenging a paradigm? Neuro-Oncology 14(12):1423CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Yu DC, Li QG, Ding XW, Ding YT (2011) Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci 12(3):2055–2063CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180(5):1808–1815CrossRefPubMedGoogle Scholar
  40. 40.
    Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, Gentile A, Mastrodonato N, Carella M, Pellegrini F, di Sebastiano P, Andriulli A (2012) Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One 7(3):e33663CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G (2012) Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem 19(4):461–474CrossRefPubMedGoogle Scholar
  42. 42.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30):10513–10518CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Reddy SD, Gajula RP, Pakala SB, Kumar R (2010) MicroRNAs and cancer therapy: the next wave or here to stay? Cancer Biol Ther 9(7):479–482CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer (Oxford, England : 1990) 43(10):1529–1544CrossRefGoogle Scholar
  45. 45.
    Jin XF, Wu N, Wang L, Li J (2013) Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 33(5):601–613CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Neurology, Xijing HospitalThe Fourth Military Medical UniversityXi’anChina
  2. 2.Department of NeurologyThe 254th Hospital of PLATianjinChina
  3. 3.State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive DiseasesThe Fourth Military Medical UniversityXi’anChina
  4. 4.Department of GastroenterologyBethune International Peace HospitalShijiazhuangChina
  5. 5.Department of NeurosurgeryThe First affiliated Hospital of the Fourth Military Medical UniversityXi’anChina

Personalised recommendations